Research programme: antibody therapeutics - Immunomedics

Drug Profile

Research programme: antibody therapeutics - Immunomedics

Alternative Names: 1R-(15)-(15); MN-14; MN-15; MN-3; MN-6

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Immunomedics
  • Class Drug conjugates; Fab fragments; Immunoconjugates; Monoclonal antibodies
  • Mechanism of Action Immunomodulators; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Autoimmune disorders; Cancer

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)
  • 04 Nov 2017 No recent reports of development identified for research development in Autoimmune-disorders in USA (Parenteral)
  • 08 Mar 2016 Immunomedics has patent protection for anti-histone antibody in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top